

BIO-TECHNE Corp  
Form 4  
August 11, 2015

**FORM 4**

**UNITED STATES SECURITIES AND EXCHANGE COMMISSION  
Washington, D.C. 20549**

OMB APPROVAL

OMB Number: 3235-0287  
Expires: January 31, 2015  
Estimated average burden hours per response... 0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

**STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP OF SECURITIES**

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934, Section 17(a) of the Public Utility Holding Company Act of 1935 or Section 30(h) of the Investment Company Act of 1940

(Print or Type Responses)

1. Name and Address of Reporting Person \*  
Gavin Robert M.

(Last) (First) (Middle)  
614 MCKINLEY PLACE NE  
  
(Street)

MINNEAPOLIS, MN 55413

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol  
BIO-TECHNE Corp [TECH]

3. Date of Earliest Transaction  
(Month/Day/Year)  
08/07/2015

4. If Amendment, Date Original Filed(Month/Day/Year)

5. Relationship of Reporting Person(s) to Issuer

(Check all applicable)

\_\_\_\_ Director \_\_\_\_\_ 10% Owner  
 Officer (give title below) \_\_\_\_\_ Other (specify below)  
Senior V.P. Protein Platforms

6. Individual or Joint/Group Filing(Check Applicable Line)  
 Form filed by One Reporting Person  
\_\_\_\_ Form filed by More than One Reporting Person

**Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned**

1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)	4. Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)	5. Amount of Securities Beneficially Owned Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Ownership (Instr. 4)
				(A) or (D)	Code V Amount (D) Price		

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

**Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB control number.**

SEC 1474  
(9-02)

**Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)**

1. Title of Derivative Security	2. Conversion or Exercise	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any	4. Transaction Code	5. Number of Derivative Securities	6. Date Exercisable and Expiration Date (Month/Day/Year)	7. Title and Amount of Underlying Securities (Instr. 3 and 4)
---------------------------------	---------------------------	--------------------------------------	-----------------------------------	---------------------	------------------------------------	--	---

Edgar Filing: BIO-TECHNE Corp - Form 4

(Instr. 3)	Price of Derivative Security	(Month/Day/Year)	(Instr. 8)	Acquired (A) or Disposed of (D) (Instr. 3, 4, and 5)	Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Stock Option (Right to Buy)	\$ 93.32								(1)	07/31/2021	Common Stock	10,000
Stock Option (Right to Buy)	\$ 93.32								(2)	07/31/2021	Common Stock	50,000
Stock Option (Right to Buy)	\$ 90.25								(3)	11/30/2021	Common Stock	5,000
Restricted Stock Units	(4)								(4)	(4)	Common Stock	5,000
Stock Option (Right to Buy)	\$ 108.49	08/07/2015		A			12,500		(5)	08/07/2022	Common Stock	12,500
Stock Option (Right to Buy)	\$ 108.49	08/07/2015		A			6,250		(7)	08/07/2022	Common Stock	6,250
Restricted Stock Units	(6)	08/07/2015		A			1,000		(7)	(7)	Common Stock	1,000

## Reporting Owners

Reporting Owner Name / Address	Relationships			
	Director	10% Owner	Officer	Other
Gavin Robert M. 614 MCKINLEY PLACE NE MINNEAPOLIS, MN 55413			Senior V.P. Protein Platforms	

## Signatures

/s/ Elizabeth M. Dunshee as Attorney-in-Fact for Robert M. Gavin pursuant to Power of Attorney filed herewith.

08/11/2015

\_\_Signature of Reporting Person

Date

## Explanation of Responses:

- \* If the form is filed by more than one reporting person, *see* Instruction 4(b)(v).
  - \*\* Intentional misstatements or omissions of facts constitute Federal Criminal Violations. *See* 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
- (1) 2,500 shares vest on each of 7/31/15, 7/31/16, 7/31/17 and 7/31/18.
  - (2) The options vest if certain performance goals are achieved for calendar 2016.
  - (3) 1,500 shares vest on each of 12/1/15, 12/1/16, 12/1/17 and 12/1/18.
  - (4) Vests in full or in part if certain performance goals are achieved for calendar 2016 (previously reported in Table I).
  - (5) 3,125 shares vest on each of 8/7/16, 8/7/17, 8/7/18 and 8/7/19.
  - (6) Each restricted stock unit represents a contingent right to receive one share of Bio-Techne common stock.
  - (7) Vests in full or in part if certain performance goals are achieved during each of the 2016, 2017 and 2018 fiscal years.

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, *see* Instruction 6 for procedure.

Potential persons who are to respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB number.